EIT Health Catapult is a training programme and competition that boosts the development of top notch European health start-ups in Biotech, Medtech and Digital Health through exposure to leading experts and international investors. The programme is organized by EIT Health with the support of the Health Axis Europe.

EIT Health Catapult provides investors/industry representatives an excellent opportunity to gain access to a concentrated elite group of top European start-up companies keen to collaborate with strong partners, when they take their first steps towards economic value creation. We would like to invite investors/industry representatives to our semifinals, in which top start-up companies from all over Europe are pitching in front of a hand-picked jury consisting of healthcare professionals with various fields of expertise after 2 days of intense mentoring and business model optimization.

**BIOTECH START-UPS**
Virtual semifinal
21 October

**MEDTECH START-UPS**
Virtual semifinal
22 October

**DIGITAL HEALTH START-UPS**
Virtual semifinal
23 October

**CONTACTS**

ANNA BADURSKA  
anna.badurska@capdigital.com

ANNA WERNER  
Anna.Werner@medical-valley-emn.de

*For general interests in Investors opportunities within EIT Health please visit EIT Health Investor Network for more info.  
https://www.eithealth.eu/en_US/investor-network*
Pitching in front of 300 selected partners (representatives from academia and industry, stakeholders and investors) and 200 external stakeholders

Investor Pitch

Pitch Training and Mentoring

Regional Selection

EIT Health Uk/Ireland

EIT Health Scandinavia

EIT Health Germany

EIT Health BeNe

EIT Health Spain

EIT Health France

InnoStars

Semifinals

European Final

EIT Health Catapult
Pitch Session at annual EIT Health Summit
BENEFITS FOR INVESTORS

BEST IN CLASS SELECTION
Profit from our pre-selection quality checks

START-UPS READY FOR INVESTMENTS
Looking for seed or series A funding

START-UP ACCESS
Make early contacts with tomorrow’s healthcare leaders scouted and preselected Europe-wide

INVESTOR READINESS PREPARATION
Start-ups are prepared to present and pitch their business ideas

EIT HEALTH INVESTORS NETWORK
Join the community and connect with the EIT Health start-up portfolio

INVESTORS’ ROUND TABLES
Meet and connect with the European Health Investor network

INVESTORS READINESS QUALITY LABEL
BENEFITS FOR EIT HEALTH CATAPULT START-UPS

VISIBILITY
Pitch in front of top level seed or series A investors of world leading medtech, biotech, pharma and IT companies.

360° INDIVIDUALIZED TRAINING
Optimize your business plan and strengthen your ability to pitch in front of top-level investors and industry experts.

PEER-TO-PEER CONNECTION
With leading innovative healthcare start-ups from all over Europe and a rich alumni programme with follow-up networking events.

PRIZE MONEY
Overall prize money of €210 000. In each category (Digital Health, Biotech & Medtech):
- 1st place €40.000
- 2nd place €20.000
- 3rd place €10.000

SERVICES
Access to the unique EIT Health Accelerator ecosystem and services in crucial areas such as clinical validation and market preparation for internationalization.
BENEFITS FOR EIT HEALTH CATAPULT START-UPS

TO INFINITY...

After participating in any EIT Health Accelerator Programme, entrepreneurs become part of our family. Whether you incubated your business idea, validated your concept, or scaled your business... We invite you to stay engaged. Entrepreneurs can continue to validate their business and personal skills by applying to other programmes or continuously utilizing our VALIDATE line. They may access our living labs, our mentors, and tap into opportunities to meet investors by working with the regional Business Creation Managers. Possibility to be invited to pitch at mayor healthcare innovation events in Europe and abroad.

AND BEYOND...

Stay in touch with the community by being involved in the EIT Health Alumni Network. Here we provide training and career opportunities, aiming at enhancing the wider EIT Health community and spur healthcare innovation. This all encompassing network connects students, professionals and entrepreneurs. The network highlights the pathways between all programmes across the three pillars : Education, Accelerator and Innovation. A joint trajectory with forward momentum.
SEMIFINALISTS

BIOTECH

Double Bond Pharmaceutical AB
www.doublebp.com

Gelmetix
www.gelmetix.com

Good Gut
www.goodgut.eu

HIQ Nano
www.hiqnano.com

Lenio Bio
www.leniobio.com

Medetia
www.medetia.com

Medi Sieve
www.medisieve.com

Neobiomics
www.neobiomics.eu

Omnigen
http://business.omnigen.nl

PanaceAR
https://www.facebook.com/panacear

PhagoMed
www.phagomed.com

Seekyo
www.seekyo-therapeutics.com

Senolytic Therapeutics
www.senolytx.com

UVera
www.uvera.eu

DIGITAL HEALTH

Blyott
www.blyott.com

Brain Scan
www.brainscan.ai

Cardi Link
www.cardi-link.com

Healthy Mind
www.healthymind.fr

Imageens
www.imageens.com

Living Brain
www.livingbrain.de

Methinks
www.methinks.es

Mii Care
www.miicare.co.uk

Patch AI
www.patchai.io

Popit
www.popit.io

Sani Nudge
www.saninudge.com

Smart Soft
www.smart-soft.net

Spotlab
www.spotlab.org/

Vittrue Health
www.vittruehealth.com

MEDTECH

AgenT
www.agent-biotech.com

Amparo
www.amparo.world

Aortyx
www.aortyx.com

Chundsell
www.chundsell.com

Confocal
www.confocal.nl

CRIAM
www.criamtech.com

Gradient
www.gradienttherapeutics.com

Newborn Solutions
www.newborn.solutions

Ondosis
www.ondosis.com

Peragraft
www.peragraft.de

RT Safe
www.rt-safe.com

Sentinel Biosensor
www.sentinelbiosensor.co.uk

STIL
www.stilwearable.com

Vitrue Health
www.vitruehealth.com

Zoan BioMed Ltd
www.zoanbiomed.com
Double Bond Pharmaceutical AB focus on the development and commercialization of innovative first-class approaches for the treatment of cancers and infections.

Glioblastoma is one of the deadliest human cancers. The success of the treatment depends on the total elimination of the tumor after brain surgery, something that rarely happens. DBP is developing SI-053, a novel gel formulation that by local administration allows immediate treatment, improving both patient survival and quality of life. We have received the orphan drug designation by EMA (2016) and the SME Instrument Phase I funding (2019). We are seeking 3M € to cover our multi-site phase 1 clinical trial by Q1 2021.
Gelmetix designs bio-inductive gels that modify cell behavior to treat patients suffering from chronic lower back pain and osteoarthritis.

Our lead product, the DMX gel, is an injectable gel that is used to treat degenerative disc disease, the cause of 40% of all chronic lower back pain cases. The gel is designed to restore cell function, relieve pain and prevent further degeneration of the intervertebral disc. We have approval to start the First-In-Human clinical trials in Bordeaux this year. We are raising money to complete both this pilot study and the pre-clinical programme for our second product addressing small joint osteoarthritis.
RAID-CRC is non-invasive low-cost patented test that determines CRC bacterial signature in fecal samples, reducing 28% of colonoscopies and increasing CRC sensitivity to 98%.

Colorectal cancer (CRC) is the 2nd cause of mortality worldwide. Guidelines recommend screening in asymptomatic adults >age50. The most used non-invasive test for CRC screening is faecal immunochemical test. Although its sensitivity for CRC is 75% and for precancerous lesions is 29%, it has a high false-positive rate implying 30% of unnecessary colonoscopies. RAID-CRC is non-invasive low-cost patented test that determines CRC bacterial signature in fecal samples, reducing 28% of colonoscopies and increasing CRC sensitivity to 98%. We are seeking 5M€ for a final clinical validation and obtaining CE-mark. RAID-CRC implementation will save 60M€ in unnecessary colonoscopies per year such in UK.
HiQ-Nano is a start-up company born with the goal to develop innovative ideas and out-of-the-box approaches in the field of point-of-care diagnostics, home testing, and colorimetric assays powered by an extensive know-how on nanomaterials.

HiQ-Nano has a broad portfolio of products, including high-quality nanomaterials for the R&D sector of major companies and universities, colorimetric diagnostic devices for home testing, and POC tests for pharmacogenomics and predictive healthcare. Following an extensive R&D process, the company is launching a new test kit for a healthy lifestyle, iBlue. iBlue is the first antioxidant test to achieve portability, long-term stability, room-temperature, and user-friendly operation.
LenioBio is disrupting the way proteins are made: with our proprietary cell-free protein production platform ALiCE®.

ALiCE® is fast, versatile, mobile, and rapidly scalable – an ideal PPP: a pandemic preparedness platform – and attributable to a broad range of further applications.

LenioBio holds an exclusive license from Dow/Corteva to develop and market the platform. Our ALiCE® expression kit and protein services generate revenues and open doors for strategic partnerships. LenioBio focuses now on scaling the technology to industrial scale. We received Seed funding and a Horizon 2020 grant in 2019. To accelerate the scaling process LenioBio seeks further investment of 5 to 7 M €.
Medetia, a biotech founded in 2019, aims to develop a first-in-class treatment for ciliopathies, an emergent type of rare diseases with a high unmet need.

Medetia is leveraging a combination drug re-development and discovery by means of a strong partnership with the Institute Imagine, a world leader center in genetic diseases (in which Medetia is located). Founded by former Alexion R&D directors, Medetia recently secured exclusive rights for the use of MDT-110 in severe renal and retinal ciliopathies; and 1.5 M€ in seed to complete the preclinical stage. Medetia is now seeking 5 M€ to engage a Phase-I trial by 2023, with a possibility for market extension and chronic treatment.
MediSieve is developing an extracorporeal therapy called “magnetic blood filtration” (MBF), a revolutionary method of treating blood-borne diseases by removing harmful substances directly from a patient’s bloodstream. The technology is similar to dialysis: a patient’s blood is circulated through an external blood loop. While dialysis relies on non-specific, size-based filtration, MBF uses functionalised magnetic particles which bind to specific targets, and magnetic forces to extract them. Practically any target can be removed including specific cells, inflammatory cytokines, pathogens and antibodies, providing a platform to treat a huge range of medical conditions and accessing several billion-dollar global markets. Solutions are being developed for hyperinflammation (sepsis, cytokine release syndrome (CRS), COVID-19), leukaemia, and severe malaria. MediSieve is currently looking to do an €8M Series A round, having raised over €4.6M in past rounds and grants.
Neobiomics provides ProPrems® - a high-quality probiotics food supplement that safely supports the intestinal microbiota in preterm infants.

Research evidence shows that food supplementation with probiotics halves the risk of necrotizing enterocolitis, a life-threatening intestinal disease in preterm infants. However, supplementation with probiotics has not become a widespread practice due to manufacturing quality concerns.

Neobiomics, rooted in academic neonatal medicine, has solved this problem by providing ProPrems® - a high-quality probiotics food supplement that safely supports the intestinal microbiota in preterm infants. We have delivered 10,000 portions to leading NICUs in Austria, Netherlands, Sweden and UK. Through a successful market launch, we aim to make ProPrems® standard-of-care for all preterm infants in Europe.
Pancreatic cancer treatment is extremely costly due to its relative ineffectiveness and treatment of non-responders.

Our solution eliminates chemotherapy treatment in cases where non-response can be predicted, saving costs and unnecessary adverse side-effects. With circa ~458,000 patients every year, the treatment costs of FOLFIRINOX amount to >27.48 billion EUR yearly, of which 45.3% is spent on non-responders. PITA as a companion diagnostics method would reduce costs with >12.44 billion EUR yearly spend on non-responders and non personalised treatment. Next to these dire economical numbers treatment of non-responders will be avoided opening the way to humane palliative treatment.
PanaceAR’s mission is to develop groundbreaking applications in diagnosis and treatments of life-threatening diseases.

It is the aim of the company to develop a Theranostic Pathology Platform based on tissue necrosis that improves the quality of life for people suffering from a wide range of diseases and conditions such as burns, chronic wounds and cancers. Our next short-term goal is to develop and optimize NecroSense, our clinically applicable necrosis-targeting probe in severe Burns. We want to achieve all the regulatory milestones to obtain CE marking approval within two years and half. We are seeking 2.5 million euros to fulfil these objectives.
Antibiotics are failing due to resistances, inactivity on biofilms and because they disrupt the ‘good’ microbiome.

PhagoMed develops phage-based drugs that work where antibiotics fail and are selective. Our lead asset is a first-in-class therapy to treat Bacterial Vaginosis (BV), the #1 vaginal infection. Our patented lysin PM-477 kills the antibiotic-resistant biofilm that forms in the vagina. It is also completely inactive vs. the beneficial Lactobacilli in the vagina, so it combines efficacy and precision. Our other assets target UTI and implant infections. PhagoMed is now raising a €16 million Series A to bring PM-477 through initial clinical trials and to expand our phage-tech platform.
Seekyo is a privately-owned biotech company that develops the next generation of chemotherapies.

By targeting the microenvironment of solid tumors while sparing healthy tissues, our lead compound SKY01 provides efficient treatments without adverse effects, improving quality of life for cancer patients. Thanks to its technology, Seekyo’s Smart Drugs are designed to transport potent anticancer agents in an innocuous manner towards safe tissues, recognize specificities of the tumor microenvironment and release the active drug in a stringently controlled fashion following an enzymatic activation. Founded in 2018, the company is based in Poitiers, France.
Senolytic Therapeutics (STX) discovers novel medicines that target cellular senescence. Damaged senescent cells drive aging and their elimination is a unique strategy to treat age-related disorders.

This has sparked the emergence of a senescence-biotech industry. Since 2017, STX has exploited knowledge and expertise in the field to discover a superior generation of senescence-related therapies. STX serves as a launchpad from which assets are capitalized. STX successfully capitalized an asset into a US-based company invested by Life Biosciences and licensed another to a Swiss-based group. STX opens a €6m round to consolidate our pipeline including a FIH trial with a clinical-stage asset.
UVera is a fusion of innovation and interdisciplinary approach to skin protection against UV sun radiation.

Our mission is to provide natural, safe, stable & eco-friendly UV protection with concomitant decrease in negative environmental impact. Regular chemical UV filters may cause DNA damage and could be strong allergens. What’s more they are responsible for destruction of coral reefs and marine ecosystem. There’s clear need for new and natural UV filters. We provide the solution. For the first time unique microorganisms are used to produce a natural UV-protection compound on an industrial scale. We are looking for 4,5M EUR investment to construct a BioFactory and run sales in 2022. Global cosmetic brands are already interested in our solution.
Plug & play solution to track and monitor assets in order to achieve big savings and happy staff.

Using existing infrastructure Blyott gives health organisations remote insights into their assets. Via a native app. No more searching. Eliminating equipment surplus and reducing maintenance cost. Sterilisable Blyott tags last for 5 years and can be used for locating, monitoring (temperature/movement). Through machine learning technique a hospital can track and monitor within several days.
Based on the analysis of more than 116,596 brain CT scans, we developed a CE certified BrainScan.ai system.

BrainScan system based on Artificial Intelligence enables automatic detection and classification of pathological changes occurring in CT examinations of the brain. That provides doctors with additional information that allows for a faster and more efficient interpretations. We help radiologists interpret brain CT scans faster and more confidently by using machine learning methods to generate valuable data.
We ensure AEDs work when needed.

AEDs (Automated External Defibrillators) have to be on the spot and fully deployable at the time of emergency. In reality, as much as 30% of AEDs installed have been found deficient or dislocated. CardiLink ensures that installed AEDs from multiple manufacturers can save lives at time of need. We deliver 24/7 AED readiness. We reduce the cost of your service, generate quality reports, and support your compliance criteria with data. We charge a small monthly fee per installation.

CardiLink, GmbH was founded in 2016 as a vendor neutral surveillance and monitoring service for AEDs. The company generated first revenues in 2018 and has trippled revenues in 2019. We are now sourcing additional capital to manage our growth potential for 2020/2021.
Healthy Mind is a company specializing in innovative medical devices based on Digital Therapeutics (DTx).

We offer healthcare facilities an evidence-based medical device aimed to alleviate the pain and anxiety of their hospitalized patients. Our therapeutic solution consists of immersive experiences in virtual reality created with renowned healthcare professionals. The medical software integrates advanced psychological principles like medical hypnosis and breath control. By using the brain’s cognitive capacities, we modulate pain pathways through visual and auditory stimulations, attention diversion, and cognitive behavioral therapy.
IMAGEENS’ AI-powered platform helps vascular surgeons deliver precision / personalized medicine.

By applying AI & biomechanical modelling to MRIs, our algorithms measure patients’ vascular stiffness, hemodynamics, and anatomy. Having been designed during the world-famous MESA trial (4000+ patients over 10 years), and having enabled 70+ publications across 22+ leading clinical centers worldwide, IMAGEENS’ offers the most clinically-validated solution for vascular function analysis by MRI. We are now combining our platform with large medical databases to help vascular surgeons make better & more cost-effective pre-surgical decisions for vascular diseases (carotid stenoses & aortic aneurysms).
Patients of neurological diseases additionally suffer from cognitive impairment often. More than 4.5 million people are affected in Germany per year.

Current rehabilitation is treatment with pencil-paper- or PC-exercises, which does not transfer to daily life (scientifically proven). Living Brain combines immersive VR, psychological learning strategies and activities of daily living for delivering a functional, gamified rehabilitation. The conduction of clinical trials and collaboration with many stakeholders from healthcare ensure the quality of the training. The startup has won several awards and received financing in 2019. Living Brain revolutionizes cognitive rehabilitation.
Methinks vision is to provide universal and timely diagnosis to life-saving treatments worldwide.

Our first focus is in stroke, the second cause of death and a major cause of disability worldwide. In Stroke, «time is brain». The chances of disability can increase up to 15% every hour stroke treatment is delayed. Stroke treatment leverages in contrast medical imaging which is not always available in many hospitals and increases time-to-treatment. We have developed an AI medical imaging software capable of triage stroke and unlock stroke treatments potential from non-contrast CTs, reducing time-to-treatment in a range of 30min to 1h and thus, saving thousands of lives and disabilities.
miiCUBE monitors the activities of the elderly in their home to keep them healthier, happier, and more connected.

This includes movement and “vitals” such as temperature and oxygen saturation. It builds a behavioural model to provide insight of activities and raises alerts if it detects risks or changes in behaviour. A mobile and web app provides family and carers with up-to-date information. Our target market is the elderly who are not digitally connected which is worth £8bn. Our route to market will be through B2B & B2B2C. After considerable research with the elderly, we built miiCUBE and have deployed 61 across the UK. We have partnerships that include the NHS and various industries.
The current standard of services for data collection offers paper tools or digital solutions characterized by limited reliability, questionable quality of data collected, poor ability to maintain patient engagement and create a personalized experience during the later phases of clinical research.

PatchAi Srl is an Italian innovative start-up borned in August 2018 aiming to transform clinical research by virtue of focus on patient centricity and forefront digital technologies though digital health solutions dedicated to safer, faster and affordable medical product development for the betterment of patients’ lives.
50% of patients do not take medications as prescribed. This causes avoidable costs and patients are not getting the best possible treatment outcomes.

Popit is working with the world’s largest pharma companies, like Pfizer and Novartis on tackling the $400Bn problem of medication non-adherence. Our solution is simple. Make medication connected! Our small device is attached onto a pill blister, the packaging format for 80% of solid drugs. By using our patented sensor technology, we can automatically detect when a medication has been taken. The medically certified app reminds if a dose has been missed. The platform can also be used for research, such as for COVID-19. Now raising €1,8M to scale up sales and expand portfolio.
The burden of hospital acquired infections (HAI) is one of the biggest threats to human survival.

According to the World Health Organization the best way to prevent HAIs is improving hand hygiene in hospitals. Sani nudge is the only holistic system to tackle this problem by actively and consistently change behaviour of healthcare workers to ensure lasting improvement of hand hygiene with actionable data insight about their hygiene. The data is generated by the first fully battery-driven hospital RTLS system. The solution is installed at 12 locations and have experienced hand hygiene compliance improvements up to 300, which have lowered short term sick leave of nurses by 72% and contributed to 64% fewer hospital acquired infections.
SmartSoft is a company that applies AI, machine learning, data capture and computer vision since its foundation.

Smart Soft has developed CoLumbo - software for analysis and diagnostics of lumbar spine images obtained with MRI. CoLumbo assists with the reading of MRI images and provides information on detected pathologies and abnormalities, provides complete diagnosis and thus reduces the time to record the readings while increasing the accuracy. Back pain is the most common cause of job-related disability and the main reason for missed workdays. Total spending on L-Spine MRI readings is more than 1B Euro worldwide.
SpotLab brings a digital ecosystem leveraging mobile technology and artificial intelligence for digitalization and remote analysis of medical images.

SpotLab brings a powerful digital ecosystem for remote and automated analysis of medical images, that combines low-cost hardware devices made out of 3D-printing and smartphones for image acquisition and advanced and intelligent software components based on artificial intelligence. SpotLab’s technology is at TRL 8. CE marking is envisioned for Q2 2020, and sales will start in Q3. Currently, the digital ecosystem is being tested worldwide in reference clinical institutions. The company has been granted a H2020 SME ph2 and is seeking an investment round of up to €1M. SpotLab’s mission is to contribute to Universal Health Coverage by 2030, by reducing time, distances and costs of medical diagnosis.
Vitrue Health (backed by Techstars) is on a mission to change the way musculoskeletal (MSK) conditions are assessed and treated across healthcare.

We’re already working in multiple settings with world leading knee surgeons, professional sports clubs and leading corporate health providers. Physiotherapy is one of the last areas of medicine where clinicians must rely on their sight alone to diagnose patients. Vitrue Health’s computer vision and biomechanics based technology is changing that with quantitative and beautiful assessment reports that improve outcomes and that patient’s love.
AgenT is developing the first blood diagnosis to detect Alzheimer’s up to 20 years before dementia.

The numerous clinical trials failures confirm we must detect and treat early but currently there is no effective way to detect pre-symptomatic disease. And without prevention, the number of patients will reach 150 million by 2050. Only company supported by France Alzheimer, AgenT has combined multiomics assays with advanced machine learning techniques to develop a neural network based on 25 biomarkers specific to Alzheimer’s. The algorithm achieved 100% sensitivity and 99% specificity during a clinical validation on 232 human blood samples frozen and sampled up to 15 years before the dementia.
Company name: Amparo
Country: GERMANY
Contact person: Lucas Paes de Melo
Email: Lucas@amparo.world
Website: www.amparo.world
CLC: Germany

Amparo GmbH (Germany) is redefining prosthetic socket technology.

Amparo is revolutionising the entire prosthetics industry by offering mobile fitting solutions. It’s disruptive product, the Confidence Socket, can be fitted to lower limb amputees anywhere in the world in less than 1h. Plus, the material is remoldable, so it can be reused, saving significant costs to health providers.

Based in Berlin, Amparo is present in 24 countries from all continents. Empowering amputees is a mission the entire team takes very seriously. Composed of 10 incredible multi-disciplinary-internationals, Amparo has the passion and competence to change the world. So far, 2M € in funding were already raised and its looking for additional 1M € for its growth phase.
Aortyx is a Barcelona-based start-up emerged from IQS School of Engineering and Hospital Clínic.

Aortyx is developing a novel family of endovascular devices that allow for endogenous regeneration of the aorta instead of artificial replacements. Focused on tissue regeneration by mimicking the aorta biomechanical environment, this technology aims at increasing the survival rates of aortic diseases patients. With mortalities as high as 50% proper treatment of such diseases is a moral imperative and presents an economic opportunity of almost 3 billion euros nowadays. Aortyx’ first product is at pre-clinical stage nowadays, with first-in-human planned for 2021 and approval by 2025.
Prostate cancer is one of the most common forms of cancer, and every year 1.3 million men are diagnosed worldwide.

Current diagnostic tools cannot accurately assess whether a cancer is aggressive or not, which leads to over- and undertreatment. A large proportion of patients undergo unnecessary radical treatment with serious side effects and huge costs for the health care system. Prostatype is a unique prognostic gene test that will help doctors and patients to make the correct treatment decision. The test will help to maintain the quality of life for the prostate cancer patient and save costs for the health care system. Chundsell is currently raising 5M€ in order to enter new markets.
Confocal.nl develops and sells upgrade modules for microscopes based on Re-scan innovation (RCM).

The upgrade uses a very sensitive sensor making the images sharper and expanding the range of colours that microscopes can detect. RCM-NIR is the only confocal microscope able to detect near infrared (NIR) light. Due to good tissue penetration properties, NIR dyes are used during fluorescence guided surgeries to label cancer cells for efficient removal. The RCM-NIR is a perfect tool for research of such dye compounds in cells and tissues, and pathologists assisting such surgeries.
CRIAM is a patented portable in vitro diagnostic company providing rapid analysis for blood-type, sub-type, diseases and nutrients.

The device can be used anywhere and in multiple scenarios such as inside an emergency vehicle while moving or in hard to reach locations without internet or power. Thanks to our machine learning and computer vision technology the device is more than five times faster and, at least, 10x more affordable than in-house hospitals diagnostics while maintaining an accuracy of 99.77%. CRIAM was already validated by the market with recommendation letters from major international players in the healthcare ecosystem and LOI´s from multiple health-care distributors around the globe.
Gradient Denervation technologies is developing a minimally invasive approach for the treatment of pulmonary hypertension.

Pulmonary hypertension (PH) is a devastating, very rapidly evolving disease, for which therapeutic options are available for less than 15% of patients. The role of nervous suractivity in causing PH is well-known. Gradient is developing a minimally invasive intravascular procedure to treat overactive nerves leading to the pulmonary artery, offering a unique therapeutic option to the millions of patients in a therapeutic dead-end. This unique approach is intended to slower the progression of the disease and improve the quality of life of PH patients.
We develop in-house first-in-class patented medical devices, software and disposables to non-invasively detect and monitor infectious diseases in serous body fluids, a market worth 30B€.

Our business model is based on sales of products, disposables and data-based functionalities for the different applications in our scope, starting with infant meningitis, via global commercialisation companies. A partial or total sale of the company to an industrial leader is expected in 2023-2025 after having shown market adoption with CE/FDA marked products through local commercialisation agents or local medical device distributors. Target buyers include medical device companies with a strategic focus on infections or in ultrasounds.
OnDosis develops a new way for patients to take their medicines.

The OnDosis device is a 1st in category device for oral solid medicines which allows for digitally controlled dosing of medicines in a flexible manner. An app supports patient adherence and symptom logging and online dashboards for HCPs enables remote monitoring. With collected data from wearables and sensors, the platform supports HCPs in setting an individualized dose - closing the disease management loop. The solution is applicable to oral solid medicines formulated as granules, powders or mini tablets and targets diseases like Epilepsy, Pediatrics, ADHD, Pain and next wave Oncology medicines. Customized to the specific medicine and commercialized as a drug/device, OnDosis is designed for commercial success through licensing to PharmaCo’s.
PerAGraft develops patient individualised implants for cardiovascular applications.

We combine an end-to-end digital process chain with an innovative textile manufacturing process. Our approach is to merge product- and process-based innovation into novel tailored implants using a fast and reliable implant design process to perfectly match the patient's needs. The unique textile structure enables a high variability and flexibility in design. Our first product is a personalised stent graft to treat complex aortic aneurysms. Combining speed, precision and simplicity, our goal is to deliver best-in-class treatment through tailored implant solutions to define a new era in patient-centred care.
RTsafe’s PseudoPatient is the first FDA-cleared, patient-specific, anatomically-exact model of human head and brain regarding its interaction with radiation utilized in Radiotherapy (RT).

RT is one of the major weapons against cancer. Despite RT high-tech maturity, safety issues do exist particularly when brain is treated, where side-effects can cause severe conditions. PseudoPatient is offered to clinics for simulating and testing radiation therapy for each patient, before their actual treatment, maximizing patient safety and treatment effectiveness. It is patented for the EU, USA, China and other countries. PseudoPatient addresses 4M brain cancer cases annually, creating a new market of €6b.
Company name: SENTINEL
Country: The United Kingdom
Contact person: Dave Hurhangee
Email: Davehurhangee@sentinelsensor.co.uk
Website: www.sentinelsensor.co.uk
CLC: UK-Ireland

**Sentinel Biosensor** develop wearable, continuous, vital-signs monitors that have medical-grade accuracy with consumer levels of usability for use in hospitals and in patient’s homes.

Sentinel Biosensor develop wearable, continuous, vital-signs monitors that have medical-grade accuracy with consumer levels of usability for use in hospitals and in patient’s homes. Sentinel was selected for the E.U. project Nightingale to develop the next-generation of vital-signs monitors. Chosen from over 198 other solutions including designs from Philips, Medtronic, SNAP40 and many others. Sentinel also won a Horizon 2020 Seal of Excellence award in 2019. In-light of the COVID-19 pandemic, we also developed C-Detect which continuously monitors for abnormal vital-signs. When detected, the user is prompted to self-isolate and be tested. C-Detect has advanced orders for 350k units by Q4 2020.
A tremor is an involuntary shake, commonly seen in the hands of people with Parkinson’s Disease and Essential Tremor.

Tremor is not lethal, but seriously obstructs over 22 million people worldwide in daily living. Current treatments are inefficient; limited tremor reduction with severe side effects. There is a huge need for something new. STIL is developing a brace that stabilizes tremor with the concept of noise-cancelling. By applying an anti-vibration to the wrist, the tremor is reduced up to 90%. By 2021, we will launch our medical device via a B2C subscription model (€100 p/m). The aim is to be reimbursed by 2023 and to make an exit before 2025 to a large industry partner.
Zoan BioMed design and develop orthopedic devices through the sustainable cultivation of tropical marine coral, delivering disease free, natural, safe, and effective bone graft solutions for surgeons.

An ageing population is the prime market driver for sector growth and Zoan has capacity to generate revenues of ca €100m through an innovation pipeline addressing the most pressing clinical needs in bone repair.
Visit our website:
eithealhealthcatapult.eu

@EITHealth
/EITHealth
/eithealhealth

Run by
With the support of
And organised by

cap-digital
BioRN
EIT Health
MEDICAL VALLEY
medicen
Health Axis Europe

EIT Health is supported by the EIT, a body of the European Union